Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersanaâs lead product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersanaâs platform to advance their ADC pipelines. Source
No articles found.
Flexion Therapeutics is a biopharmaceutical company focused on the development and...
Flexion Therapeutics is a biopharmaceutical com...
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to im...
Five Prime Therapeutics, Inc. discovers and dev...
CAVU Biotherapies offers a comprehensive solution to prepare for, monitor, and tre...
CAVU Biotherapies offers a comprehensive soluti...
PLUS THERAPEUTICS is a clinical-stage pharmaceutical company focused on making a p...
PLUS THERAPEUTICS is a clinical-stage pharmaceu...
Join the National Investor Network and get the latest information with your interests in mind.